0001193125-26-210675
SEC filingDeepening losses driven by paused clinical programs and increased R&D spending, with cash runway into mid-2027.
For the first quarter of fiscal 2026, Aardvark Therapeutics reported an operating loss of $22.5 million, compared to $10.5 million in the same period last year, a 114.6% increase. This widening loss was primarily driven by increased research and development expenses associated with the clinical development of ARD-101 and other pipeline programs, as well as the pause of the Phase 3 HERO trial. Net loss for the quarter was $21.6 million, or $0.99 per diluted share, versus $9.3 million, or $0.71 per diluted share, in the prior year period.
The company faces significant pricing pressures from managed care and legislative changes, which could affect future product revenues. Additionally, regulatory and legal risks related to healthcare laws and data privacy may increase operational complexity and costs. The stock market and biopharmaceutical sector have experienced extreme volatility, which may not reflect the company's operating performance. Management does not anticipate paying dividends, making capital appreciation the sole potential return for investors.